53 results about "Filaggrin" patented technology

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.

The invention discloses a cyclic chimeric citrullinated peptide antigen and an application thereof. The preparation of the cyclic chimeric citrullinated peptide antigen comprises the following steps: firstly connecting and jogging three small-molecular antigen peptides, namely a citrullinated peptide1, a citrullinated peptide 2 and a citrullinated peptide 3 derived from a silk polymerizing protein/an intermediate filament protein, and then synthetizing a cyclic polypeptide with a similar protein beta-corner structure by forming a disulfide bond through two cysteines inserted into the end N and the end C of a chimeric peptide. The cyclic chimeric citrullinated peptide antigen coats a solid-phase vector to prepare an indirect enzyme linked immunosorbent assay kit used for detecting the hypotype of multiple anti-citrullinated protein antibodies contained in RA (Rheumatoid Arthritis) serum. The cyclic chimeric citrullinated peptide antigen and the ELISA kit thereof which are disclosed by the invention have the advantages of simple preparation and experimental operation process, good result repeatability, qualification or quantification and wide clinical application and scientific research value and are outstandingly enhanced in detection sensibility and diagnosis value on RA compared with an international similar kit.

The invention provides the use of silica for cosmetic and/or medical treatment of skin, including improving and enhancing the skin-barrier, anti-aging treatment and photo-protective treatment. The invention is based on the finding that silica exhibits a multi-faceted biological effect useful in the cosmetic and/or therapeutic treatment of skin for the above purposes. Specifically, it has been shown that silica induces markers (involucrin, filaggrin and transglutaminase-1) for skin barrier formation in keratinocytes, induces collagen expression in dermal fibroblasts and inhibits UVA-induced up-regulation of photo-aging markers (matrix metalloproteinase MMP-1 and cytokine IL-6).

The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression of filaggrin and involucrin that are skin-moisturizing factors, and thus to provide excellent anti-drying and skin-moisturizing effects. More particularly, the composition for external skin application may further comprise theobromine and quercetin in addition to gallocatechin gallate to maximize such effects.

[PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor.

[SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient.

[EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and β-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

The invention provides a moisturizing mask and a preparation method thereof. The moisturizing mask comprises the following components, by weight: 0.01 to 1% of saccharide isomeride, 0.01%-1% of rhizobium gum, 0.01%-1% of tremella extract, 0.01%-0.2% of sodium hyaluronate, 0.01%-1% of codium tomentosum extract, 0.04%-1.5% of a skin conditioner, 0.1%-0.3% of a pH regulator, 0.06%-0.45% of a thickener and the balance being water. According to the moisturizing mask, various moisturizing active matters are mixed based on a scientific proportion; gene expression of filaggrin, loricrin, hyaluronan synthase-3 and acid sphingomyelinase in the skin can be up-regulated and the water locking capacity of the skin can be improved; meanwhile, synthesis of ceramide and cerebroside is promoted, absorptionof the skin to surrounding moisture is improved, so that the purpose of efficient moisturizing is achieved.

The application belongs to the technical field of lysates and skin care, and particularly relates to a bifidobacteria lysate and a preparation method thereof. The preparation method of the bifidobacteria lysate provided by the invention comprises the following steps of performing fermentation on bifidobacteria in culture fluid containing millet extracting solutions, performing centrifuging and performing crushing, so that the bifidobacteria lysate is obtained. The bifidobacteria lysate disclosed by the invention can effectively promote expression of intermediate filament relevant proteins between keratinocytes, including filaggrin FLG, loricrin LOR, involucrin IVL, keratin KRT-10 and para-transglutaminase TGM-1, further contributes to transformation of the keratinocytes to cuticle, and isquite important in the respect of maintaining integrity of skin barriers.

Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids 416-766).

The invention relates to a moisturizing agent containing hot spring minerals. The moisturizing agent is prepared from the following components in percentage by weight: 1.50% of phenoxy ethanol, 0.50% to 1.5% of sodium carrageenan, 0.05% of mineral salt and 96.95% to 97.95% of water. The moisturizing agent containing the hot spring minerals has the following beneficial effects of being capable of strongly capturing water molecules in skin surface air, and forming a water retention film to reduce skin water loss, further being capable of promoting the synthesis of epidermal hyaluronic acid and the synthesis of tight junction protein-1 to increase epidermal tightness, and promoting the synthesis of ceramide and degradation of filaggrin to form more natural moisturizing factors, thereby having high-efficient moisturizing and reconstructing effects, and further having a skin moisturizing and smoothing effect which is faster and more effective than that of the hyaluronic acid, and still having an effect which is better than that of the hyaluronic acid after being continuously used for 22 weeks.

Autoantibodies reacting against citrullinated peptides derived from C-telopeptides of type I and type II collagens are found in patients with rheumatoid arthritis. They detect sequences —YYXA from α1 or —FYXA from α2 chain of type I collagen or —YMXA from α1 chain of type II collagen, where X is citrulline. The antibodies are different from anti-filaggrin antibodies. The peptides of the invention can be used in diagnosis of rheumatoid arthritis. Oral administration of citrullinated peptides can induce tolerance and lead to the treatment of rheumatoid arthritis.

The invention is directed to a method for non-invasive determination of the potential presence of one or more loss-of-function mutation(s) in the gene encoding for filaggrin.

The method of the invention comprises

• (i) obtaining a vibrational spectrum from the stratum corneum of the individual;
• (ii) determining the local natural moisturising factor content from the vibrational spectrum;
• (iii) optionally repeating steps (i) and (ii); and
• (iv) comparing the local natural moisturising factor content of the individual to a reference value,
• wherein said stratum corneum is stratum corneum of a location of the body of said individual at which said one or more loss-of-function mutation(s) in the gene encoding for filaggrin has a stronger influence on the natural moisturising factor concentration than other factors influencing the natural moisturising factor concentration.

The present invention relates to a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in treating skin or mucosa barrier dysfunctions or defects. The present invention also comprises the use of a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in the manufacture of a medicament for use in treating skin barrier dysfunctions. Also disclosed is a use of a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in the manufacture of a cosmetic composition for use in improving the appearance and/or texture of the skin. The present invention also comprises a method of treating skin barrier dysfunctions comprising administering a composition comprising Lactobacillus rhamnosus GG (LGG) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin.

The invention discloses an anti-crease finishing agent for a shirt fabric and an application of the anti-crease finishing agent. The anti-crease finishing agent comprises the following components in parts by weight: 1-5 parts of nano titanium dioxide, 12-18 parts of malic acid, 20-30 parts of isopropyl alcohol, 8-14 parts of sodium sulfate, 20-30 parts of plant extract, 2-8 parts of silk protein,2-4 parts of sorbitan fatty acid ester, 18-27 parts of amino silicone oil, 1-3 parts of organosilicone emulsion, 3-8 parts of coconut fatty acid diethanol amide, 35-40 parts of modified polyurethane,2-8 parts of sodium carboxymethyl cellulose oxide, and 30-48 parts of deionized water. Compared with the prior art, the anti-crease effect of the shirt fabric is improved by using the silk protein andthe modified polyurethane, and the lubricity of the silk protein improves the affinity of the fabric and the skin. In addition, the plant extract is obtained by mixing of multiple plants, extractionand concentration, thereby reducing the addition of chemicals while ensuring the anti-crease effect of the finishing agent.

The invention discloses an application of a composition in preparation of a skin barrier gene repair preparation. The composition includes the following components: a scutellaria baicalensis root extract, a sophora flavescens root extract, and a glycyrrhiza inflata root extract; and the application includes the aspect of using the composition to regulate expression of at least one protein or enzyme selected from the group consisting of keratin, filaggrin (FLG), loricrin (LOR), involucrin, transglutaminase, aquaporin, caspase-14 (CASP14). The preparation fills the blank of the composition of the three extracts of the scutellaria baicalensis, the sophora flavescens and the glycyrrhiza inflata in the repair of genes related to skin barrier in the prior art, and especially, the preparation, genes related to formation of cornified envelope (CE), such as the LORE and the FLG and a gene related to filaggrin degradation, such as the CASP14 lay the foundation for subsequent treatment of skin diseases related to the skin barrier.

The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease.

The invention relates to use of plant fermented extracts, especially relates to the use of imperata cylindrica fermented extract for enhancing the gene expression of keratin, filaggrin and hyaluronansynthase, promoting the proliferation of collagen and elastin, and enhancing antioxidant capacity of skin cells. The invention provides the imperata cylindrica fermented extract by performing two-stage fermentation on an imperata cylindrica water extract with saccharomycetes and lactic acid bacillus. The invention further provides the uses of the imperata cylindrica fermented extract for preparing a composition enhancing the expression quantity of keratin, filaggrin and hyaluronan synthase, promoting the proliferation of collagen and elastin, and enhancing antioxidant capacity of skin cells.The imperata cylindrica fermented extract can effectively improving the moisturizing capacity of skin, maintaining the arrangement of keratinocyte and the completeness of cuticle structure, thus improving the shield function of skin, making skin compact and elastic, and preventing aging of skin.

The present specification relates to a composition comprising processed ginseng extract and processed green tea extract. Such a composition results in having a synergistic effect due to mixing of each processed extract, and is thus capable of promoting the production of procollagen and inhibiting the expression of collagenase. In addition, the composition of the present specification promotes the expression of filaggrin and is thus capable of strengthening a skin barrier function and inducing the differentiation of skin keratinocytes. Therefore, the composition of the present specification is capable of improving the general condition of skin, and can be effectively used as an external preparation for skin for preventing or improving xeroderma, atopic dermatitis, contact dermatitis, psoriasis, or the like that is caused by the imperfection of epidermal differentiation.

The invention relates to the field of medicine, in particular to an application of quinine and pharmaceutically acceptable salts thereof to preparation of a drug for treating AD (atopic dermatitis) and the drug for treating AD. A mouse model of AD is established by an embodiment, a skin lesion region of a mouse is smeared with a physiological saline solution of quinine, and the skin lesion is found to be obviously reduced. Further research shows that quinine can obviously reduce the pathological injury of the mouse, activate expression of a bitter taste receptor and silk polymerization protein, inhibit IgE in blood of the mouse and secretion of cytokines such as IL-1beta, IL-4, IL-5, IL-13 and IL-33 in skin lesion tissue, and thus, improve the skin condition, enhance the skin barrier function, inhibit occurrence of allergic reaction, relieve skin damage caused by immune reaction, and play a safe and effective role in treating the skin damage caused by AD. The invention expands medicalapplications of quinine and provides a new direction for treatment of AD.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide (e.g., a human laminin polypeptide) and/or a filaggrin polypeptide (e g , a human filaggrin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Junctional Epidermolysis Bullosa); and articles of manufacture or kits thereof.

The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of Phoenix dactylifera extract, tea tree oil, Myrothamnus flabellifolia extract, and saccharide isomerate. This combination can be used to create topical skin compositions that reduce rosacea, erythema, and/or inflammation, and inhibit nitric oxide synthase, increase α2A adrenergic receptor agonist activity, reduce oxidation, increase anti-oxidant capacity of a composition or of skin, inhibit cyclooxygenase-2 (COX-2) production, inhibit vascular endothelial growth factor (VEGF) production, inhibit interleukin-6 (IL-6) and interleukin-8 (IL-8) production, reduce tumor necrosis factor alpha (TNF-α) production, increase collagen stimulation, increase lysyl oxidase expression, inhibit matrix metalloproteinase 1 (MMP1) activity, increase occludin production, increase filaggrin production, and increase skin moisturization. This combination can also be used to reduce transient or persistent erythema, telangiectasia, inflammatory papules and/or pustules, transient or persistent flushing of the skin, and/or hyperplasia of a connective tissue.